terazosin has been researched along with Body Weight in 12 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety and efficacy of once-daily terazosin as monotherapy were evaluated in five randomized, double-blind, placebo-controlled studies in which 351 patients with mild to moderate hypertension participated." | 9.06 | Terazosin: an effective once-daily monotherapy for the treatment of hypertension. ( Dauer, AD, 1986) |
| "In a multicenter, double-blind, placebo-controlled study, the efficacy and safety of terazosin and prazosin were compared in patients with mild to moderate essential hypertension." | 9.06 | Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. ( Deger, G, 1986) |
| "The long-term treatment of essential hypertension with terazosin, a new once-a-day alpha 1-adrenergic blocking agent, was evaluated in 364 hypertensive patients who received total daily doses of 1 to 40 mg for 3 weeks to 56 months." | 9.06 | Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension. ( Estep, CB; Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Schmitz, PJ, 1988) |
| "Two hundred twenty-six patients with mild to moderate hypertension were treated with terazosin in an open, multicenter study to determine the drug's long-term efficacy and safety." | 7.67 | Long-term experience with terazosin for treatment of mild to moderate hypertension. ( Mersey, JH, 1986) |
| "The safety and efficacy of once-daily terazosin as monotherapy were evaluated in five randomized, double-blind, placebo-controlled studies in which 351 patients with mild to moderate hypertension participated." | 5.06 | Terazosin: an effective once-daily monotherapy for the treatment of hypertension. ( Dauer, AD, 1986) |
| "In a multicenter, double-blind, placebo-controlled study, the efficacy and safety of terazosin and prazosin were compared in patients with mild to moderate essential hypertension." | 5.06 | Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. ( Deger, G, 1986) |
| "The long-term treatment of essential hypertension with terazosin, a new once-a-day alpha 1-adrenergic blocking agent, was evaluated in 364 hypertensive patients who received total daily doses of 1 to 40 mg for 3 weeks to 56 months." | 5.06 | Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension. ( Estep, CB; Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Schmitz, PJ, 1988) |
| "Two hundred twenty-six patients with mild to moderate hypertension were treated with terazosin in an open, multicenter study to determine the drug's long-term efficacy and safety." | 3.67 | Long-term experience with terazosin for treatment of mild to moderate hypertension. ( Mersey, JH, 1986) |
| "The safety of terazosin, an effective agent for the treatment of hypertension, was assessed by analyzing data from 1,006 hypertensive patients who were enrolled in short-term and/or long-term studies." | 3.67 | Overall safety of terazosin as an antihypertensive agent. ( Glassman, HN; Jordan, DC; Luther, RR; Sperzel, WD, 1986) |
| "High sodium diet (HS, 8% NaCl) induces left ventricular hypertrophy (LVH) in normotensive rats without an increase in pressure or volume load or in resting cardiac sympathetic activity." | 1.30 | alpha- and beta-adrenoceptor blockade fail to prevent high sodium diet-induced left ventricular hypertrophy. ( Harmsen, E; Leenen, FH; Song, D, 1997) |
| "Hydralazine was the only drug to alter the lipid peroxidation level in the myocardium of SHR rats (a 28% decrease), but in WKY rats all three drugs caused significant decreases in myocardial lipid peroxidation levels." | 1.30 | Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels. ( Cabell, KS; Johnson, P; Ma, L, 1997) |
| " In both the SHR and WKY, chronic administration of terazosin did not influence vascular concentrations of 3-methylhistidine, a biochemical marker for contractile proteins and vascular medial hypertrophy." | 1.28 | Effect of alpha 1-adrenoceptor blockade on the development of hypertension in the spontaneously hypertensive rat. ( Frewin, DB; Head, RJ; Jonsson, JR, 1992) |
| " Under these conditions the LD50 was 277 mg/kg for males and 293 mg/kg for females." | 1.27 | Terazosin: intravenous safety evaluation in rats. ( Cusick, PK; Fort, FL; Heyman, IA; Kesterson, JW; Majors, K; Tekeli, S, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (50.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Papay, R | 1 |
| Zuscik, MJ | 1 |
| Ross, SA | 1 |
| Yun, J | 1 |
| McCune, DF | 1 |
| Gonzalez-Cabrera, P | 1 |
| Gaivin, R | 1 |
| Drazba, J | 1 |
| Perez, DM | 1 |
| Fort, FL | 1 |
| Tekeli, S | 1 |
| Majors, K | 1 |
| Heyman, IA | 1 |
| Cusick, PK | 1 |
| Kesterson, JW | 1 |
| Semplicini, A | 1 |
| Valle, R | 1 |
| Serena, L | 1 |
| Fazari, G | 1 |
| Fontebasso, A | 1 |
| Gebbin, A | 1 |
| De Toni, R | 1 |
| Pessina, AC | 1 |
| Song, D | 1 |
| Harmsen, E | 1 |
| Leenen, FH | 1 |
| Cabell, KS | 1 |
| Ma, L | 1 |
| Johnson, P | 1 |
| Jonsson, JR | 1 |
| Head, RJ | 1 |
| Frewin, DB | 1 |
| Ferrari, P | 1 |
| Rosman, J | 1 |
| Neuner, N | 1 |
| Shaw, S | 1 |
| Riesen, W | 1 |
| Weidmann, P | 1 |
| Dauer, AD | 1 |
| Deger, G | 1 |
| Mersey, JH | 1 |
| Sperzel, WD | 1 |
| Glassman, HN | 2 |
| Jordan, DC | 2 |
| Luther, RR | 2 |
| Estep, CB | 1 |
| Schmitz, PJ | 1 |
| Horton, JK | 1 |
3 trials available for terazosin and Body Weight
| Article | Year |
|---|---|
Terazosin: an effective once-daily monotherapy for the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Do | 1986 |
Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Do | 1986 |
Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Female; Humans; Hypertension | 1988 |
9 other studies available for terazosin and Body Weight
| Article | Year |
|---|---|
Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.
Topics: Adrenergic alpha-Antagonists; alpha-Synuclein; Animals; Body Weight; Brain; Cerebellum; Disease Mode | 2002 |
Terazosin: intravenous safety evaluation in rats.
Topics: Animals; Antihypertensive Agents; Blepharoptosis; Body Temperature; Body Weight; Dose-Response Relat | 1984 |
Long-term alpha-1 adrenoceptor blockade does not affect plasma atrial natriuretic peptide in hypertensive patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Atrial Natriuretic Fac | 1994 |
alpha- and beta-adrenoceptor blockade fail to prevent high sodium diet-induced left ventricular hypertrophy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Body Weight; Dri | 1997 |
Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Enzyme Activation; Heart; | 1997 |
Effect of alpha 1-adrenoceptor blockade on the development of hypertension in the spontaneously hypertensive rat.
Topics: Adrenergic alpha-Antagonists; Animals; Biomarkers; Blood Pressure; Body Weight; Hemodynamics; Hypert | 1992 |
Postsynaptic alpha 1-blockade with terazosin does not modify insulin sensitivity in nonobese normotensive subjects.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Glucose; Blood Pressure; Bod | 1991 |
Long-term experience with terazosin for treatment of mild to moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Dru | 1986 |
Overall safety of terazosin as an antihypertensive agent.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Asthenia; Body Weight; Dizziness; Female; Hea | 1986 |